Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.
Advocates counter FDA’s problems with Duchenne muscular dystrophy treatment's trial data using real-life experience.